©2024 Stanford Medicine
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Not Recruiting
Trial ID: NCT02178943
Purpose
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in
association with the measurement of AlloMap, a non-invasive gene expression test to aid in
heart transplant management.
Official Title
Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)
Stanford Investigator(s)
Kiran Kaur Khush, MD
Professor of Medicine (Cardiovascular Medicine)
Eligibility
Inclusion Criteria
1. Any heart transplant recipient eligible for initiation and participation in the
Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.
2. Patients can be enrolled any time as long as they have not had more than 1 prior
AlloMap.
3. Written informed consent must be obtained prior to study enrollment. Exclusion
Criteria
1. Pregnant Women.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Helen Luikart
650-724-2883